#United States #Waltham #Q32 Bio #Alopecia Areata #ajeva

Q32 Bio Strengthens Leadership Team

In a strategic move to enhance its clinical capabilities, Q32 Bio Inc. has appointed two accomplished professionals to its leadership team. Dr. José Trevejo has taken the role of Chief Medical Officer (CMO), while Dr. Ellie Hershberger has been named Chief Development Officer (CDO). This transition comes as Q32 Bio prepares to navigate into a late clinical stage of its operations, particularly in the development of bempikibart, a treatment aimed at alopecia areata and various autoimmune conditions.

The New Additions

Dr. José Trevejo boasts over 20 years of experience within the biotechnology sector, notably in dermatology and advanced clinical development. His previous roles have included serving as Chief Medical Officer for Enveda Therapeutics, where he took the reins on clinical pipeline strategy and helped propel several projects toward clinical stages, including a candidate for atopic dermatitis. His robust background in medicine and clinical research uniquely positions him to lead Q32 Bio's medical advancements.

Dr. Ellie Hershberger, bringing more than 30 years of expertise in drug development, will take charge of overseeing the company’s strategic initiatives related to drug development operations and regulatory strategy. Before joining Q32 Bio, she was at Adagio Therapeutics (now known as Invivyd), where she guided a monoclonal antibody candidate through critical clinical stages. Her extensive knowledge in navigating regulatory landscapes is essential for Q32’s aim to fulfill its development milestones efficiently.

Vision for Advanced Treatments

Both executives will be integral in pushing the development of bempikibart, which has shown promising results in recent clinical trials, particularly in the SIGNAL-AA program. Early data suggests that patients experienced significant hair regrowth along with a good safety profile, indicating that this therapy could offer a substantial improvement over current treatment options available for alopecia areata, a condition affecting approximately 700,000 individuals in the United States alone.

Jodie Morrison, CEO of Q32 Bio, expressed the significance of these appointments, stating, “José and Ellie join Q32 Bio at a pivotal moment as we transition into a late clinical stage company... We are thrilled to welcome them to the Q32 Bio team.” Their combined expertise is expected to steer the company's efforts in advancing bempikibart into registration-focused programs in 2027.

Commitment to Patients

Dr. Trevejo echoed these sentiments as he regarded the opportunity to make a meaningful impact on patients dealing with alopecia areata and other autoimmune diseases. He expressed enthusiasm about working alongside the Q32 Bio team in realizing the potential of bempikibart, noting, “Based on the results to date, bempikibart has the potential to address key limitations of currently available therapies.” This indicates a strong commitment to improving patient outcomes through innovative treatment development.

Meanwhile, Dr. Hershberger expressed her eagerness to build upon the existing frameworks established by the SIGNAL-AA project and expand bempikibart's potential applications. She highlighted the organization's focused trajectory towards clinical success, resonating with Q32 Bio's overall mission to address pressing healthcare needs through cutting-edge biopharmaceutical advancements.

As Q32 Bio forges ahead with these strategic appointments, it sets a precedent for unwavering dedication to patients and the pursuit of ground-breaking therapies tailored for autoimmune disorders. The synergy between its new CMO and CDO is anticipated to not only accelerate the development of bempikibart but also enhance the broader portfolio of the company.

About Q32 Bio

Q32 Bio stands at the frontier of clinical-stage biotechnology, innovating therapies rooted in the modulation of the adaptive immune system. The company’s commitment to improving the lives of those suffering from autoimmune diseases through targeted therapies showcases its mission to achieve transformative healthcare solutions. Interested parties can follow the company's progress via its official website at www.Q32Bio.com.